Detalhe da pesquisa
1.
Effectiveness and safety of belantamab mafodotin in patients with relapsed or refractory multiple myeloma in real-world setting: The ALFA study.
Eur J Haematol
; 2024 May 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38722078
2.
Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 study.
Haematologica
; 108(10): 2774-2782, 2023 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37078253
3.
Survival outcomes for patients with multiple myeloma in France: A retrospective cohort study using the Système National des Données de Santé national healthcare database.
Eur J Haematol
; 111(1): 125-134, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-37199133
4.
Treatment patterns and overall survival of patients with double-class and triple-class refractory multiple myeloma: a US electronic health record database study.
Leuk Lymphoma
; 64(2): 398-406, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36408998
5.
Assessing the treatment pattern, health care resource utilisation, and economic burden of multiple myeloma in France using the Système National des Données de Santé (SNDS) database: a retrospective cohort study.
Eur J Health Econ
; 24(3): 321-333, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-35610398
6.
Treatment preferences of patients with relapsed or refractory multiple myeloma in the United States, United Kingdom, Italy, Germany, France, and Spain: results from a discrete choice experiment.
Front Med (Lausanne)
; 10: 1271657, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38076274
7.
Perioperative glucose management and outcomes in liver transplant recipients: A qualitative systematic review.
World J Transplant
; 8(3): 75-83, 2018 Jun 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-29988867
8.
A small molecule fibrokinase inhibitor in a model of fibropolycystic hepatorenal disease.
World J Nephrol
; 7(5): 96-107, 2018 Sep 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30211028